Xia et al., 2021 - Google Patents
Decreased NSG3 enhances PD-L1 expression by Erk1/2 pathway to promote pancreatic cancer progressXia et al., 2021
View HTML- Document ID
- 15531531331177163811
- Author
- Xia X
- Li R
- Zhou P
- Xing Z
- Lu C
- Long Z
- Wang F
- Wang R
- Publication year
- Publication venue
- American Journal of Cancer Research
External Links
Snippet
Inhibiting the functioning of PD-1/PD-L1 to activate human immune system and improve the prognosis of pancreatic cancer (PC) would provide a significant boost to handling the disease. One research found the expression level of NSG3 was reduced in pediatric …
- 102100001472 CALY 0 title abstract description 139
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kong et al. | CD44 promotes PD-L1 expression and its tumor-intrinsic function in breast and lung cancers | |
| Osa et al. | Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients | |
| Osipov et al. | From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy | |
| Guo et al. | Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models | |
| Jackson et al. | Sequential single-cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with non-Hodgkin lymphoma | |
| Herling et al. | High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia | |
| Dutcher | Recent developments in the treatment of renal cell carcinoma | |
| Jing et al. | BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer | |
| Cheng et al. | Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle | |
| Lopez et al. | Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas | |
| Jian et al. | Interleukin 7 receptor activates PI3K/Akt/mTOR signaling pathway via downregulation of Beclin‐1 in lung cancer | |
| Liu et al. | Synergistic effect of ibrutinib and CD19 CAR‐T cells on Raji cells in vivo and in vitro | |
| US20190284640A1 (en) | Methods and Systems for Predicting Response to Immunotherapies for Treatment of Cancer | |
| Porciuncula et al. | Spatial Mapping and Immunomodulatory Role of the OX40/OX40L Pathway in Human Non–Small Cell Lung Cancer | |
| Xia et al. | Decreased NSG3 enhances PD-L1 expression by Erk1/2 pathway to promote pancreatic cancer progress | |
| Liu et al. | Synergistic killing effects of PD-L1-CAR T cells and colorectal cancer stem cell-dendritic cell vaccine-sensitized T cells in ALDH1-positive colorectal cancer stem cells | |
| US20210395831A1 (en) | Biomarkers to improve efficacy of cancer immunotherapy | |
| Liu et al. | Discovery of a novel, potent and selective small‐molecule inhibitor of PD‐1/PD‐L1 interaction with robust in vivo anti‐tumour efficacy | |
| Ma et al. | c‐KIT‐ERK1/2 signaling activated ELK1 and upregulated carcinoembryonic antigen expression to promote colorectal cancer progression | |
| Hu et al. | M351‐0056 is a novel low MW compound modulating the actions of the immune‐checkpoint protein VISTA | |
| Lin et al. | Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment | |
| Vanmeerbeek et al. | Targeting conserved TIM3+ VISTA+ tumor-associated macrophages overcomes resistance to cancer immunotherapy | |
| Saha et al. | Serine Depletion Promotes Anti-Tumor Immunity by Activating Mitochondrial DNA-mediated cGAS-STING Signaling | |
| Martincuks et al. | Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer | |
| Zhang et al. | BAFF receptor antibody for mantle cell lymphoma therapy |